Clinical Trials Directory

Trials / Unknown

UnknownNCT04221399

Type 2 Diabetes Patients With Renal Impairment

A Single- and Multiple-Dose Clinical Study to Evaluate Pharmacokinetics and Pharmacodynamics of DWP16001 Following Oral Dose in Type 2 Diabetes Patients With Renal Impairment

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
35 (estimated)
Sponsor
Daewoong Pharmaceutical Co. LTD. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate the effect of kidney function on pharmacokinetics and pharmacodynamics of DWP16001 following single and multiple oral doses in type 2 diabetes patients with normal kidney function and renal impairment.

Conditions

Interventions

TypeNameDescription
DRUGDWP16001Tablets, Oral, Once daily, Single dose
DRUGDWP16001Tablets, Oral, Once daily, Multiple dose

Timeline

Start date
2020-01-01
Primary completion
2020-08-01
Completion
2020-10-01
First posted
2020-01-09
Last updated
2020-01-09

Source: ClinicalTrials.gov record NCT04221399. Inclusion in this directory is not an endorsement.

Type 2 Diabetes Patients With Renal Impairment (NCT04221399) · Clinical Trials Directory